Biological activity of heterologous murine interleukin-10 and preliminary studies on the use of a dextrin nanogel as a delivery system

International Journal of Pharmaceutics

Volumn 400, Issue 1-2, 2010, Pages 234-242

  Carvalho, Vera ^a   Castanheira, Pedro ^b   Faria, Tiago Q ^c   Gonçalves, Catarina ^a   Madureira, Pedro ^d,e   Faro, Carlos ^b,f   Domingues, Lucília ^a   Brito, Rui M M ^c,g   Vilanova, Manuel ^d,e   Gama, Miguel ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b Biocant Molecular Biotechnology Unit   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anti inflammatory cytokine; Dextrin nanogel; Endotoxin activated macrophages; Interleukin 10; Protein delivery system

Indexed keywords

DEXTRIN; ENDOTOXIN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CIRCULAR DICHROISM; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; FLUORESCENCE ACTIVATED CELL SORTER; GEL; MACROPHAGE; MOUSE; NANOGEL; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS;

ANIMALS; DELAYED-ACTION PREPARATIONS; DEXTRINS; DOWN-REGULATION; DRUG CARRIERS; ESCHERICHIA COLI; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERLEUKIN-10; MACROPHAGES; MICE; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957652256     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.040     Document Type: Article

References (41)

1. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55:241-269.
2. Ball C., Vigues S., Gee C.K., Poole S., Bristow A.F. Rat interleukin-10: production and characterisation of biologically active protein in a recombinant bacterial expression system. Eur. Cytokine Netw. 2001, 12:187-193.
3. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 2001, 1:209-219.
4. Bogdan C., Vodovotz Y., Nathan C. Macrophage deactivation by interleukin 10. J. Exp. Med. 1991, 174:1549-1555.
5. Bondoc L.L., Varnerin J.P., Tang J.C. Resolution of recombinant human interleukin 10 from variants by recycling free flow focusing. Anal. Biochem. 1997, 246:234-238.
6. Carvalho J., Gonçalves C., Gil A.M., Gama F.M. Production and characterization of a new dextrin based hydrogel. Eur. Polym. J. 2007, 43:3050-3059.
7. Creery W.D., Diaz-Mitoma F., Filion L., Kumar A. Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur. J. Immunol. 1996, 26:1273-1277.
8. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991, 174:1209-1220.
9. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 1991, 174:915-924.
10. Defrance T., Vanbervliet B., Briere F., Durand I., Rousset F., Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J. Exp. Med. 1992, 175:671-682.
11. Dyson M.R., Shadbolt S.P., Vincent K.J., Perera R.L., McCafferty J. Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC Biotechnol. 2004, 4:32.
12. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147:3815-3822.
13. Gazzinelli R.T., Oswald I.P., James S.L., Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J. Immunol. 1992, 148:1792-1796.
14. Gonçalves C., Martins J.A., Gama F.M. Self-assembled nanoparticles of dextrin substituted with hexadecanethiol. Biomacromolecules 2007, 8:392-398.
15. Gonçalves C., Torrado E., Martins T., Pereira P., Pedrosa J., Gama M. Dextrin nanoparticles: studies on the interaction with murine macrophages and blood clearance. Colloids Surf. B: Biointerfaces 2009, 75:483-489.
16. Gonçalves C., Gama F.M. Characterization of the self-assembly process of hydrophobically modified dextrin. Eur. Polym. J. 2008, 44.
17. Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 1998, 160:3188-3193.
18. Hreczuk-Hirst D., Chicco D., German L., Duncan R. Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. Int. J. Pharm. 2001, 230:57-66.
19. Hubel K., Dale D.C., Liles W.C. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interferon-gamma. J. Infect. Dis. 2002, 185:1490-1501.
20. Josephson K., DiGiacomo R., Indelicato S.R., Ayo A.H., Nagabhushan T.L., Parker M.H., Walter M.R. Design and analysis of an engineered human interleukin-10 monomer. J. Biol. Chem. 2000, 275:13552-13557.
21. Kim S., Kim J.H., Jeon O., Kwon I.C., Park K. Engineered polymers for advanced drug delivery. Eur. J. Pharm. Biopharm. 2009, 71:420-430.
22. Leonard M., De Boisseson M.R., Hubert P., Dalencon F., Dellacherie E. Hydrophobically modified alginate hydrogels as protein carriers with specific controlled release properties. J. Control Release 2004, 98:395-405.
23. Ma J., Chen T., Mandelin J., Ceponis A., Miller N.E., Hukkanen M., Ma G.F., Konttinen Y.T. Regulation of macrophage activation. Cell. Mol. Life Sci. 2003, 60:2334-2346.
24. MacNeil I.A., Suda T., Moore K.W., Mosmann T.R., Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol. 1990, 145:4167-4173.
25. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
27. Murthy N., Thng Y.X., Schuck S., Xu M.C., Frechet J.M. A novel strategy for encapsulation and release of proteins: hydrogels and microgels with acid-labile acetal cross-linkers. J. Am. Chem. Soc. 2002, 124:12398-12399.
28. Murthy N., Xu M., Schuck S., Kunisawa J., Shastri N., Frechet J.M. A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4995-5000.
29. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 2004, 22:929-979.
30. Pullerits T. Cytokine modulation for anti-allergic treatment. Curr. Pharm. Des. 2002, 8:1845-1853.
31. Sorensen H.P., Mortensen K.K. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb. Cell Fact. 2005, 4:1.
32. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997, 159:4772-4780.
33. Steinbrink K., Graulich E., Kubsch S., Knop J., Enk A.H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002, 99:2468-2476.
34. Treetharnmathurot B., Dieudonne L., Ferguson E.L., Schmaljohann D., Duncan R., Wiwattanapatapee R. Dextrin-trypsin and ST-HPMA-trypsin conjugates: enzyme activity, autolysis and thermal stability. Int. J. Pharm. 2009, 373:68-76.
35. Tushinski R.J., Oliver I.T., Guilbert L.J., Tynan P.W., Warner J.R., Stanley E.R. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 1982, 28:71-81.
36. Walter M.R., Nagabhushan T.L. Crystal structure of interleukin 10 reveals an interferon gamma-like fold. Biochemistry 1995, 34:12118-12125.
37. Willems F., Marchant A., Delville J.P., Gerard C., Delvaux A., Velu T., de Boer M., Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 1994, 24:1007-1009.
38. Windsor W.T., Syto R., Tsarbopoulos A., Zhang R., Durkin J., Baldwin S., Paliwal S., Mui P.W., Pramanik B., Trotta P.P., et al. Disulfide bond assignments and secondary structure analysis of human and murine interleukin, 10. Biochemistry 1993, 32:8807-8815.
39. Zdanov A., Schalk-Hihi C., Gustchina A., Tsang M., Weatherbee J., Wlodawer A. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 1995, 3:591-601.
40. Zdanov A., Schalk-Hihi C., Wlodawer A. Crystal structure of human interleukin-10 at 1.6 A resolution and a model of a complex with its soluble receptor. Protein Sci. 1996, 5:1955-1962.
41. Zhang, X., Gonçalves, R., Mosser, D.M., 2008. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14, Unit 14 11.